for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chembio Diagnostics Inc

CEMI.OQ

Latest Trade

4.18USD

Change

0.90(+27.44%)

Volume

2,793,098

Today's Range

3.50

 - 

4.38

52 Week Range

2.25

 - 

15.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.28
Open
3.73
Volume
2,793,098
3M AVG Volume
55.38
Today's High
4.38
Today's Low
3.50
52 Week High
15.88
52 Week Low
2.25
Shares Out (MIL)
20.17
Market Cap (MIL)
84.30
Forward P/E
-4.17
Dividend (Yield %)
--

Next Event

Q2 2020 Chembio Diagnostics Inc Guidance Call

Latest Developments

More

Chembio To Work With FDA Regarding Revoked Clearance For COVID-19 Test

FDA Revokes Emergency Use Authorization for Chembio Antibody Test

Chembio Diagnostics Receives FDA 510(K) Clearance For DPP Zika IgM System

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chembio Diagnostics Inc

Chembio Diagnostics, Inc. is a provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. The Company is primarily focused on expanding its product portfolio based upon its Dual Path Platform (DPP). The Company's products include rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The Company’s point-of-care infectious disease portfolio is comprised of multiple commercial products and are performed with a tiny drop of blood from the fingertip and provide results in approximately 15 minutes. The Company’s products include DPP HIV 1/2, DPP HIV-Syphilis, DPP Syphilis Screen and Confirm, DPP Zika, DPP Leishmaniasis, STAT-PAK HIV 1/2, STAT-PAK Chagas, SURE CHECK HIV 1/2 and SURE CHECK HIV 1/2 Self- Test.

Industry

Biotechnology & Drugs

Contact Info

555 Wireless Blvd

HAUPPAUGE, NY

11788-3966

United States

+1.631.9241135

http://chembio.com/

Executive Leadership

Katherine Lyon Davis

Non-Executive Independent Chairman of the Board

Richard L. Eberly

President, Chief Executive Officer

Neil A. Goldman

Chief Financial Officer, Executive Vice President

Javan Esfandiari

Chief Science and Technology Officer

Chuck Caso

Vice President of Sales and Marketing for North America

Key Stats

3.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.520

2018

-0.550

2019

-0.810

2020(E)

-1.003
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.55
Price To Book (MRQ)
3.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
99.90
LT Debt To Equity (MRQ)
99.02
Return on Investment (TTM)
-38.92
Return on Equity (TTM)
-32.77

Latest News

Latest News

Chembio shares slump as FDA revokes emergency use of COVID-19 test

Shares of Chembio Diagnostics Inc slumped more than 60% on Wednesday after the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization for its COVID-19 antibody test kit on concerns about its accuracy.

BRIEF-Chembio To Work With FDA Regarding Revoked Clearance For COVID-19 Test

* CHEMBIO DIAGNOSTICS - INTEND TO CONTINUE WORKING WITH FDA WITH RESPECT TO MODIFICATION OF DPP COVID-19 SYSTEM - SEC FILING

BRIEF-FDA Revokes Emergency Use Authorization for Chembio Antibody Test

* FDA SAYS REVOKES EMERGENCY USE AUTHORIZATION FOR CHEMBIO ANTIBODY TEST

BRIEF-Chembio Diagnostics Receives FDA 510(K) Clearance For DPP Zika IgM System

* CHEMBIO DIAGNOSTICS RECEIVES FDA 510(K) CLEARANCE FOR DPP ZIKA IGM SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics Announces US Distribution Agreement To Expand Reach Of DPP Covid-19 Serological Test

* CHEMBIO DIAGNOSTICS ANNOUNCES US DISTRIBUTION AGREEMENT TO EXPAND REACH OF DPP COVID-19 SEROLOGICAL TEST WITH THERMO FISHER SCIENTIFIC’S HEALTHCARE CHANNEL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Chembio Diagnostics Announces Proposed Public Offering Of Common Stock

* CHEMBIO DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics Attains CE Marking For Dpp Covid-19 System For Igg And Igm Antibodies

* CHEMBIO DIAGNOSTICS ATTAINS CE MARKING FOR DPP COVID-19 SYSTEM FOR IGG AND IGM ANTIBODIES Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics Posts Q1 Revenue Of $6.9 Million

* CHEMBIO DIAGNOSTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Chembio Diagnostics Says Co Through Unit Entered Into Loan Agreement With HSBC Bank Usa, National Association, Refered To As PPP Loan

* CHEMBIO DIAGNOSTICS - ON APRIL 20, CO THROUGH UNIT ENTERED INTO LOAN AGREEMENT WITH HSBC BANK USA, NATIONAL ASSOCIATION, REFERED TO AS PPP LOAN

BRIEF-Chembio Diagnostics Receives Emergency Use Authorization For DPP Covid-19 System For IgG And IgM Antibodies

* CHEMBIO DIAGNOSTICS RECEIVES EMERGENCY USE AUTHORIZATION FOR DPP COVID-19 SYSTEM FOR IGG AND IGM ANTIBODIES Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics And Stony Brook Medicine Collaborate To Identify Coronavirus Survivors

* CHEMBIO DIAGNOSTICS AND STONY BROOK MEDICINE COLLABORATE TO IDENTIFY CORONAVIRUS SURVIVORS

BRIEF-Chembio Receives Second UNICEF Order For $1.5 Mln

* CHEMBIO DIAGNOSTICS INC - SECOND $1.5 MILLION PURCHASE ORDER FROM UNICEF FOR MULTIPLEX ZIKA, CHIKUNGUNYA AND DENGUE SYSTEMS Source text for Eikon: Further company coverage:

BRIEF-Chembio Announces Launch Of DPP COVID-19 Serological Point-Of-Care Test

* CHEMBIO ANNOUNCES LAUNCH OF DPP COVID-19 SEROLOGICAL POINT-OF-CARE TEST

BRIEF-Chembio Diagnostics Receives $4 Mln Purchase Order From Bio-Manguinhos For Production Of DPP COVID-19 IGM/IGG System In Brazil

* CHEMBIO DIAGNOSTICS RECEIVES $4 MILLION PURCHASE ORDER FROM BIO-MANGUINHOS FOR PRODUCTION OF DPP COVID-19 IGM/IGG SYSTEM IN BRAZIL Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics Reports Q4 Loss Per Share Of $0.23

* CHEMBIO DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Chembio Diagnostics Appoints Richard Eberly As Chief Executive Officer

* CHEMBIO DIAGNOSTICS APPOINTS RICHARD EBERLY AS CHIEF EXECUTIVE OFFICER

BRIEF-Chembio And Lumiradx Announce Covid-19 Strategic Partnership

* CHEMBIO AND LUMIRADX ANNOUNCE COVID-19 STRATEGIC PARTNERSHIP

BRIEF-Chembio Diagnostics Has Accelerated Studies For Clia Waiver

* CHEMBIO DIAGNOSTICS PROVIDES UPDATE ON REGULATORY STATUS OF DPP HIV-SYPHILIS SYSTEM

BRIEF-Chembio Diagnostics Receives $1.5 Mln Unicef Order For Multiplex Zika Systems

* CHEMBIO DIAGNOSTICS RECEIVES $1.5 MILLION UNICEF ORDER FOR MULTIPLEX ZIKA SYSTEMS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Chembio Diagnostics Reports Q1 Loss Per Share $0.05

* CHEMBIO DIAGNOSTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up